1-4 of 4
Ronald R. Hiebsch, BS
Close
Sort by
Journal Articles

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

William Casey Wilson, PhD, John Richards, PhD, Robyn J Puro, PhD, Gabriela Andrejeva, PhD, Ben J Capoccia, PhD, Mike J Donio, Ronald R Hiebsch, BS, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-139655
Published: 2020
Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1844.
https://doi.org/10.1182/blood-2019-126298
Published: 2019
Journal Articles

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

W. Casey Wilson, PhD, Myriam N Bouchlaka, BS, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, Robyn J Puro, PhD, Alun J Carter, PhD, Prabir Chakraborty, PhD, Pamela T Manning, PhD, Robert W Karr, MD, Vicki Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4180.
https://doi.org/10.1182/blood-2018-99-118456
Published: 2018
Journal Articles

Dual-Function Anti-CD47mAbs Induce Tumor Cell Death and Promote Phagocytosis Resulting in Enhanced in Vivo Efficacy

Pamela T. Manning, PhD, Benjamin J. Capoccia, PhD, Michael P. Rettig, PhD, Ronald R. Hiebsch, BS, Robert W. Karr, MD, John F. DiPersio, MD PhD, William A. Frazier, PhD
Journal: Blood
Blood (2014) 124 (21): 991.
https://doi.org/10.1182/blood.V124.21.991.991
Published: 2014